Ingredients supplier ADM has partnered with i-Health Inc. to formulate a new supplement, Culturelle Weight + Metabolism, which features ADM’s proprietary BPL1 strain.
 
ADM’s Bifidobacterium animalis subsp. Lactis BPL1 strain is supported by a portfolio of pre-clinical and clinical evidence which demonstrates its potential to confer health benefits related to metabolism and weight management. In clinical studies, daily supplementation with the strain has been linked to significant fat reduction, waist circumference reduction, increased satiety, and an antioxidant and inflammatory-modulating effect. This is due to a specific mechanism of action through which it impacts biomarkers related to metabolic health.
 
“As this is the first Culturelle product to target metabolic health and weight management, we’re proud to say it’s formulated with BPL1 and highlight the robust science that supports it,” Eric Bianco, brand lead North America at Culturelle, said.
 
“ADM invests in industry-leading microbiome research and innovation to help our partners and customers develop evidence-based solutions in a variety of applications,” Marta Tortajada Serra, vice president of Science and Technology at ADM, said. “Together we’re supporting the metabolic health needs of consumers around the world.”
 
ADM’s recent consumer research shows that nearly one-third of consumers have become more conscious about their weight, compared to just 21% of survey respondents prior to the pandemic. 38% of consumers in the U.S. have changed their views on health and wellness in the last year, and 32% of those consumers cited a change in weight as the reason why, ADM reports.
 
The company also reports an increased consumer awareness about how metabolic health can affect their overall health, especially immune and mental health, through the gut microbiome.